Zimbabwe has turned down a substantial American health deal valued at 367 million US dollars (£272m) spanning five years due to the United States' insistence on sensitive information.
This rejection came to light after a internal memorandum dated December was leaked, revealing that Head of State Emmerson Mnangagwa deemed the arrangement was "skewed".
A government spokesperson has since explained that the US was requesting biological samples for research and commercial purposes but was unwilling to share the benefits from future medical innovations.
"We will now turn to the difficult and regrettable task of ending our health aid in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had donated more than $1.9bn for health programmes to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has urged continued dialogue to find a agreement agreeable to all parties so the country's critical HIV programme can be sustained.
Broader Context
Zimbabwe's decision comes after a comparable situation in neighbouring Kenya, where a high court suspended a similar health funding agreement after concerns were raised about the safety of Kenyans' health data.
After resuming the presidency recently, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
The agency had overseen aid for the US government, but Trump claimed its spending was "inefficient" and his government was pursuing government-to-government agreements to boost openness and accountability.
According to statements, 16 African countries have to date signed these new agreements, constituting over $18.3bn in new funding.
Details of the Rejected Deal
The money for Zimbabwe was intended to gone towards "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this cooperation could have provided immense benefits for Zimbabwean communities, particularly the 1.2 million currently on antiretroviral therapy through American-funded initiatives," the Ambassador commented.
However, government spokesperson Nick Mangwana said the arrangement was "unequal".
"Our nation was requested to share its biological resources and data for a long time, with no corresponding assurance of access to any medical innovations – such as vaccines, diagnostics, or treatments – that might be developed from that provided information," he stated.
"Effectively, our nation would provide the raw materials for medical research without any assurance that the end products would be available to our population should a new disease outbreak emerge."
Sovereignty and Global Health
He also noted that the US's withdrawal from the global health body and its push of bilateral deals were undermining systems already set up via the global organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing system designed to manage potential pandemics.
"This mechanism is intended to ensure that when a nation provides its data, the resulting advantages – including medicines and cures – are shared equitably, not commercialised solely by those with the capability to develop them."
These objections regarding the US deal "are not meant as hostility towards the US," he added.
"We welcome further dialogue with our US partners on how subsequent co-operation could be arranged in a manner that honours the independence and dignity of both nations."
Health Experts Reaction
Medical experts expressed it understood the government's concerns, but suggested that negotiations need to persist since much of the country's Aids initiatives depended on external financing.
"Where technical issues arise, including those relating to information security or agreement terms, these can often be resolved via technical clarification and mutually agreed protections," the group commented.
The halted deal emphasises the continuing challenges between receiving vital international aid and protecting local interests in an ever more data-driven world.